Financials and Filings

MGEN $0.50 $ - 0.06 (11.25%)

SEC Filings

Other Filings
Filing Description Filing Type Filing Date Event Date  
Proxy PRE 14A 3/27/2020 3/27/2020
Registration Statement S-3 3/26/2020
10-K 10-K 3/13/2020 12/31/2019
Registration Statement S-8 3/13/2020
8-K 8-K 3/11/2020 3/11/2020
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Results of Operations and Financial Condition and Financial Statements and Exhibits.
8-K 8-K 2/19/2020 2/12/2020
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
13-D SC 13G/A 2/13/2020
8-K 8-K 2/7/2020 2/7/2020
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Regulation FD Disclosure; Other Events; and Financial Statements and Exhibits.
Prospectus 424B5 2/7/2020
8-K 8-K 2/6/2020 2/6/2020
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Regulation FD Disclosure; Other Events; and Financial Statements and Exhibits.
Prospectus 424B5 2/6/2020
8-K 8-K 1/30/2020 1/30/2020
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Other Events.
Prospectus 424B5 12/12/2019
8-K 8-K 12/11/2019 12/11/2019
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities; Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Regulation FD Disclosure; Other Events; and Financial Statements and Exhibits.
10-Q 10-Q 11/8/2019 9/30/2019
8-K 8-K 11/7/2019 11/7/2019
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Results of Operations and Financial Condition and Financial Statements and Exhibits.
8-K 8-K 10/31/2019 10/31/2019
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Unregistered Sales of Equity Securities; and Financial Statements and Exhibits.
8-K 8-K 10/16/2019 10/16/2019
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Other Events and Financial Statements and Exhibits.
10-Q 10-Q 8/8/2019 6/30/2019
8-K 8-K 8/7/2019 8/7/2019
Abstract: 8-K filed by Miragen Therapeutics (MGEN) covering Termination of a Material Definitive Agreement; Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities; and Financial Statements and Exhibits.

Displaying 1 to 20 (of 222 filings)